品牌咨询
联系方式
公司地址
苏州工业园区生物纳米园A4#216
联系电话
4000-520-616 / 18915418616
传真号码
0512-67156496
电子邮箱
info@ebiomall.com
公司网址
https://www.ebiomall.com

TheNativeAntigenCompany/Mouse Anti-Feline Leukemia Virus P27 Antibody (7228)/100µg/MAB12387-100

价格
¥3940.00
货号:MAB12387-100
浏览量:127
品牌:TheNativeAntigenCompany
服务
全国联保
正品保证
正规发票
签订合同
商品描述

MOUSE ANTI-FELINE LEUKEMIA VIRUS P27 ANTIBODY (7228)

Mouse anti Feline leukemia virus p27 antibody (7228) is specific for the p27 of FeLV. The antibody is suitable for enzyme immunoassay (EIA) applications (ELISA and Lateral Flow). MAB12387 can be used for capture and detection in Sandwich ELISA.

PRODUCT DETAILS – MOUSE ANTI-FELINE LEUKEMIA VIRUS P27 ANTIBODY (7228)

  • Mouse anti Feline leukemia virus p27 monoclonal antibody (7228).
  • Specific for FeLV p27.
  • Suitable for use in IFA, ELISA and Lateral Flow applications.
  • Purified by Protein G Sepharose chromatography.
  • Presented in phosphate buffered saline, pH 7.2, 0.1% sodium azide.

BACKGROUND

Feline leukemia virus (FeLV) is a widespread pathogen of the domestic cat and (Cornell University, 2016) and was first described in 1964. It is an RNA virus in the subfamily Oncovirinae belonging to the Retroviridae family. The FeLV genome contains three genes coding for the structural proteins of the virus; the group specific antigen (gag) gene, including p27; the polymerase (pol) gene coding for the reverse transcriptase, protease and integrase; and the envelope (env) gene coding for the glycoprotein gp70 and the transmembrane protein p15 E (Coffin, 1979). the total genome is ~9.6 kbp. Following synthesis of a DNA copy of the viral RNA genome, it integrates into the genome of the target cell as a provirus. This provirus remains in the genome of the cell for the life span of the cell and, upon cellular division, the viruses bud from the membrane of the infected cell, undergoing the final phase of maturation with cleavage of the Pr65 group antigen (Gag) precursor into the mature structural proteins p15 matrix (MA), p27 capsid (CA) and p10 nucleocapsid (NC).

FeLV assembles at the plasma membrane. The precursor of the viral structural proteins Pr65Gag is thought to attach to the underside of the membrane. Once bound, the Pr65Gag proteins multimerise, triggering the membrane to bend around the forming core. Env proteins associate with the nascent particle through their co-localisation on the membrane until an immature particle is formed. A scission event then takes place, releasing the immature virion, at which time the viral protease cleaves Pr65Gag into distinct matrix (MA), capsid (CA) and nucleocapsid (NC) proteins. As they bud from the infected cell, nascent virions acquire the envelope glycoprotein Env, comprising the surface (SU) glycoprotein gp70 and transmembrane (TM) protein p15E. Gp70 is the target for neutralising antibodies in recovered cats and is an essential component of FeLV vaccines (Willett and Hosie, 2013).

The prevalence of FeLV in cats has decreased significantly in the past 25 years since the development of an effective vaccine and more accurate testing procedures (Cornell University, 2016). The majority of in-practice tests for FeLV detect viral antigen (capsid protein p27) in blood, plasma or serum. P27 is the most abundant viral protein in the plasma of viraemic cats. Its utility as a diagnostic marker for FeLV viraemia is only possible because cats do not appear to respond serologically to the protein, an observation that has led to speculation that cats may be largely immunologically tolerant to p27 through exposure to endogenously expressed FeLV Gag (Willett and Hosie, 2013). Cats that clear infectious virus from the plasma will be negative by virus isolation, ELISA, immunochromatography, and IFA, but will remain positive by provirus PCR and are considered regressively infected. A small proportion (2-3 %) of cats remains positive by ELISA and immunochromatography although no infectious virus can be isolated from plasma. These cats have foci of infection outside the bone marrow from which soluble p27 is released into the circulation; such cats are potential sources of infection (Lutz et al., 1980c; Regina Hofmann-Lehmann et al., 2018).

REFERENCES

  • Coffin JM (1979). Structure, replication, and recombination of retrovirus genomes: some unifying hypotheses. J Gen Virol 42, 1-26.
  • Feline leukemia virus factsheet. Cornell University College of Veterinary Medicine, May 2016.
  • Feline leukaemia virus factsheet. Small Animal Veterinary Surveillance Network (SAVSNET), University of Liverpool, September 2019.
  • Lutz et al. (1980c): Quantitation of p27 in the serum of cats during natural infection with feline leukemia virus. In: Feline Leukemia Virus, Hardy WD, Essex M, McClelland A, (eds); Development in Cancer Res 4 , 497505, Elsevier/North Holland.
  • Regina Hofmann-Lehmann et al. (2018). Feline Leukaemia Virus Infection. Advisory Board on Cat Diseases (ABCD).
  • Willett and Hosie (2013). Feline leukaemia virus: half a century since its discovery. Vet J. 195(1):16-23.

Product datasheetSafety datasheet

Ambient

TheNativeAntigenCompany我们在测定开发方面拥有多年经验。根据具体应用,我们建议并测试多种不同的ELISA格式,从简单的直接ELISA到具有封闭抗原的间接ELISA和双抗原结合ELISA。您不仅可以从我们的高级测定开发科学家那里获得咨询的好处,而且我们的内部表达系统还可以用于生产天然折叠的和完全糖基化的蛋白质和抗体,以用作最高质量的独特试剂,从而使您的ELISA处于优势反对竞争。我们的能力包括:+   ELISA设计和格式咨询+   定制抗原和抗体生产+   使用定制抗原作为免疫原(mAbs和pAbs)产生抗体+   ELISA中的抗原/抗体对优化+   与酶结合以检测抗体+   板涂+   ELISA优化  我们可以在项目的任何阶段为您的ELISA分析的开发提供支持,  提供定制服务,这些灵活性可以评估用于分析的最佳抗体  对,直至商业套件的全面开发。 如果您的概念还处于早期阶段,那么我们可以准备您的抗原,  提高您的抗体,并使用它们来开发特定的ELISA分析以满足您的需求。